Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals reported an 11% increase in Q1 2025 net sales of DAYBUE™ in the US, with a record number of patients receiving shipments. The company anticipates further growth as two-thirds of diagnosed Rett patients have yet to try DAYBUE. Neuren’s royalty income also saw a 17% increase from the previous year, and the company is preparing for European market entry with anticipated marketing approval in Q1 2026. The expansion of Acadia’s field force and distribution agreements in various regions are expected to drive further growth.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing therapies for neurodevelopmental disorders. Its primary product, DAYBUE™ (trofinetide), is used in the treatment of Rett syndrome and has received Orphan Drug designation in Japan. The company is expanding its market reach with distribution agreements in regions including Latin America, the Middle East, and Asia Pacific.
Average Trading Volume: 703,501
Technical Sentiment Signal: Hold
Current Market Cap: A$1.54B
Learn more about NEU stock on TipRanks’ Stock Analysis page.